Please Wait
Applying Filters...
menu
    • menu
    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Virtual Booth

    Contact Supplier

    Valsynthese, part of the SSE Group, is a CDMO focused on highly energetic and highly hazardous chemistry.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    With Fermion, start the journey of your innovative API.

    Virtual Booth

    Contact Supplier

    Bloomage is a one-stop source for CEP Sodium Hyaluronate and Hyaluronic Acid// FDA-inspected & GMP-certified.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Fosdenopterin

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    UK MHRA approves Sentynl ’ Nulibry for injection a first therapy fo MoCD type A
    UK MHRA approves Sentynl ’ Nulibry for injection a first therapy fo MoCD type A

    18 Apr 2024

    // PHARMABIZ

    https://www.pharmabiz.com/NewsDetails.aspx?aid=168581&sid=2

    PHARMABIZ
    18 Apr 2024
    Share Share
    Sentynl's NULIBRY® Authorized For MoCD Type A In UK
    Sentynl's NULIBRY® Authorized For MoCD Type A In UK

    16 Apr 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/sentynl-therapeutics-receives-mhra-authorization-of-nulibry-fosdenopterin-for-treatment-of-mocd-type-a-in-great-britain-302117194.html

    PR NEWSWIRE
    16 Apr 2024
    Share Share
    Sentynl Announces Presentation of Study Evaluating the Safety of NULIBRY
    Sentynl Announces Presentation of Study Evaluating the Safety of NULIBRY

    07 Sep 2023

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/sentynl-therapeutics-announces-presentation-of-study-evaluating-the-efficacy-and-safety-of-nulibry-fosdenopterin-for-the-treatment-of-mocd-type-a-at-2023-ssiem-annual-symposium-301920794.html

    PR NEWSWIRE
    07 Sep 2023
    Share Share
    Comharsa's Nulibry (Fosdenopterin) Receives Approval in Europe
    Comharsa's Nulibry (Fosdenopterin) Receives Approval in Europe

    30 Sep 2022

    // EMA

    https://www.pharmacompass.com/pdf/news/comharsas-nulibry-fosdenopterin-receives-approval-in-europe-28956.pdf

    EMA
    30 Sep 2022
    Share Share
    BridgeBio Pharma and Sentynl Receive Marketing Authorization NULIBRY®
    BridgeBio Pharma and Sentynl Receive Marketing Authorization NULIBRY®

    20 Sep 2022

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2022/09/20/2519096/0/en/BridgeBio-Pharma-and-Sentynl-Therapeutics-Receive-Marketing-Authorization-in-the-EU-for-NULIBRY-fosdenopterin-for-the-Treatment-of-MoCD-Type-A.html

    GLOBENEWSWIRE
    20 Sep 2022
    Share Share
    BridgeBio, Sentynl and Medison Pharma Announce Approval in Israel for NULIBRY
    BridgeBio, Sentynl and Medison Pharma Announce Approval in Israel for NULIBRY

    10 Aug 2022

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2022/08/10/2495664/0/en/BridgeBio-Pharma-Sentynl-Therapeutics-and-Medison-Pharma-Announce-Approval-in-Israel-for-NULIBRY-fosdenopterin-for-the-Treatment-of-MoCD-Type-A.html

    GLOBENEWSWIRE
    10 Aug 2022
    Share Share